Carlo Gambacorti‐Passerini

43.3k total citations · 3 hit papers
342 papers, 13.7k citations indexed

About

Carlo Gambacorti‐Passerini is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Carlo Gambacorti‐Passerini has authored 342 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Hematology, 173 papers in Genetics and 84 papers in Molecular Biology. Recurrent topics in Carlo Gambacorti‐Passerini's work include Chronic Myeloid Leukemia Treatments (187 papers), Chronic Lymphocytic Leukemia Research (158 papers) and Eosinophilic Disorders and Syndromes (75 papers). Carlo Gambacorti‐Passerini is often cited by papers focused on Chronic Myeloid Leukemia Treatments (187 papers), Chronic Lymphocytic Leukemia Research (158 papers) and Eosinophilic Disorders and Syndromes (75 papers). Carlo Gambacorti‐Passerini collaborates with scholars based in Italy, United States and Germany. Carlo Gambacorti‐Passerini's co-authors include Luca Mologni, Jörge E. Cortes, Edoardo Marchesi, Tim H. Brümmendorf, Rocco Piazza, Andreas Hochhaus, François Guilhot, Brian Druker, Hagop M. Kantarjian and Philipp le Coutre and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Carlo Gambacorti‐Passerini

336 papers receiving 13.4k citations

Hit Papers

Hematologic and Cytogenetic Responses to Imatinib Mesylat... 2002 2026 2010 2018 2002 2012 2017 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    2002 1.5k citations Charles L. Sawyers, Andreas Hochhaus et al. profile →
  2. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
    2012 344 citations Jörge E. Cortes, Dong‐Wook Kim et al. profile →
  3. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    2017 320 citations Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlo Gambacorti‐Passerini Italy 56 7.9k 5.5k 5.0k 3.3k 2.9k 342 13.7k
Paul W. Manley Switzerland 50 5.9k 0.7× 4.2k 0.8× 3.4k 0.7× 2.7k 0.8× 2.0k 0.7× 153 10.6k
Gautam Borthakur United States 65 13.2k 1.7× 6.5k 1.2× 6.7k 1.3× 2.4k 0.7× 2.9k 1.0× 809 17.7k
Michael W. Deininger United States 67 16.3k 2.1× 12.5k 2.3× 4.9k 1.0× 7.5k 2.3× 3.2k 1.1× 399 21.2k
Omar Abdel‐Wahab United States 68 7.4k 0.9× 5.3k 1.0× 10.9k 2.2× 1.4k 0.4× 2.2k 0.7× 306 18.6k
Giuseppe Saglio Italy 75 18.5k 2.3× 13.4k 2.5× 5.6k 1.1× 7.0k 2.1× 4.3k 1.5× 650 25.0k
Deborah A. Thomas United States 80 12.3k 1.6× 10.2k 1.9× 6.3k 1.3× 2.6k 0.8× 4.9k 1.7× 451 23.2k
Martin Carroll United States 49 4.7k 0.6× 2.1k 0.4× 6.8k 1.4× 677 0.2× 2.6k 0.9× 200 11.7k
Srđan Verstovšek United States 84 18.6k 2.4× 18.7k 3.4× 12.1k 2.4× 8.5k 2.6× 4.4k 1.5× 1.1k 30.0k
Dolors Colomer Spain 60 2.7k 0.3× 4.9k 0.9× 5.1k 1.0× 573 0.2× 3.1k 1.1× 280 12.0k
Elisabeth Paietta United States 61 7.8k 1.0× 2.6k 0.5× 4.7k 1.0× 418 0.1× 3.0k 1.0× 278 12.9k

Countries citing papers authored by Carlo Gambacorti‐Passerini

Since Specialization
Citations

This map shows the geographic impact of Carlo Gambacorti‐Passerini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Gambacorti‐Passerini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Gambacorti‐Passerini more than expected).

Fields of papers citing papers by Carlo Gambacorti‐Passerini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Gambacorti‐Passerini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Gambacorti‐Passerini. The network helps show where Carlo Gambacorti‐Passerini may publish in the future.

Co-authorship network of co-authors of Carlo Gambacorti‐Passerini

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Gambacorti‐Passerini. A scholar is included among the top collaborators of Carlo Gambacorti‐Passerini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Gambacorti‐Passerini. Carlo Gambacorti‐Passerini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, B. Douglas, Tim H. Brümmendorf, Gail J. Roboz, et al.. (2024). Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leukemia Research. 139. 107481–107481. 1 indexed citations
2.
Iurlo, Alessandra, Cristina Bucelli, Tamara Intermesoli, et al.. (2024). Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy. Acta Haematologica. 148(4). 494–498. 1 indexed citations
3.
Mauri, Mario, Giovanni Paolo Maria Zambrotta, Daniele Ramazzotti, et al.. (2023). DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients. HemaSphere. 7(3). e852–e852. 2 indexed citations
4.
Gambacorti‐Passerini, Carlo, et al.. (2023). Analogies between COVID-19 and Preeclampsia: Focus on Therapies. SHILAP Revista de lepidopterología. 3(2). 203–216. 4 indexed citations
5.
Gambacorti‐Passerini, Carlo, Andrea Aroldi, Rocco Piazza, et al.. (2021). Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. Transfusion and Apheresis Science. 60(3). 103105–103105. 3 indexed citations
6.
Sharma, Geeta G., Mario Mauri, Diletta Fontana, et al.. (2021). Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers. 13(17). 4422–4422. 10 indexed citations
7.
Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, et al.. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 33(8). 1835–1850. 84 indexed citations
8.
Redaelli, Sara, Monica Ceccon, Geeta G. Sharma, et al.. (2018). Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. Cancer Research. 78(24). 6866–6880. 61 indexed citations
9.
Muvarak, Nidal, Carine Robert, Maria R. Baer, et al.. (2015). c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated Leukemias. Molecular Cancer Research. 13(4). 699–712. 54 indexed citations
10.
Ceccon, Monica, Luca Mologni, Giovanni De Giudici, et al.. (2014). Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research. 13(4). 775–783. 47 indexed citations
11.
Tardy, Sébastien, Alexandre Orsato, Luca Mologni, et al.. (2014). Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. Bioorganic & Medicinal Chemistry. 22(4). 1303–1312. 22 indexed citations
12.
Ceccon, Monica, Luca Mologni, William H. Bisson, Léonardo Scapozza, & Carlo Gambacorti‐Passerini. (2012). Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors. Molecular Cancer Research. 11(2). 122–132. 71 indexed citations
13.
Magistroni, Vera, Luca Mologni, James F. Reid, et al.. (2011). ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE. 6(11). e28162–e28162. 26 indexed citations
14.
Mologni, Luca, Hafedh Dekhil, Monica Ceccon, et al.. (2010). Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of β-Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. Cancer Research. 70(18). 7253–7263. 41 indexed citations
15.
Passoni, Lorena, Luca Longo, Paola Collini, et al.. (2009). Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. Cancer Research. 69(18). 7338–7346. 129 indexed citations
16.
Coluccia, Addolorata Maria Luce, Teresa Cirulli, Paola Neri, et al.. (2008). Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood. 112(4). 1346–1356. 79 indexed citations
17.
18.
Yasmeen, Amber, Tarek A. Bismar, Hafedh Dekhil, et al.. (2007). ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis. Cell Cycle. 6(23). 2939–2943. 18 indexed citations
19.
Galietta, Annamaria, Rosalind H. Gunby, Sara Redaelli, et al.. (2007). NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma. Haematologica. 92. 48–49. 1 indexed citations
20.
Gambacorti‐Passerini, Carlo, M. Cortellaro, E. Cofrancesco, et al.. (1989). Possible Mechanisms of Fibrin Deposition in the Hypereosinophilic Syndrome. Pathophysiology of Haemostasis and Thrombosis. 19(1). 32–37. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul W. Manley Breakdown of academic impact, for papers by Gautam Borthakur Breakdown of academic impact, for papers by Michael W. Deininger Breakdown of academic impact, for papers by Omar Abdel‐Wahab Breakdown of academic impact, for papers by Giuseppe Saglio Breakdown of academic impact, for papers by Deborah A. Thomas Breakdown of academic impact, for papers by Martin Carroll Breakdown of academic impact, for papers by Srđan Verstovšek Breakdown of academic impact, for papers by Dolors Colomer Breakdown of academic impact, for papers by Elisabeth Paietta
Rankless by CCL
2026